Search

Takeda Pharmaceutical Co Ltd ADR

Geschlossen

BrancheGesundheitswesen

18.05 3.8

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

17.38

Max

18.14

Schlüsselkennzahlen

By Trading Economics

Einkommen

138B

113B

Verkäufe

105B

1.2T

KGV

Branchendurchschnitt

42.622

57.371

EPS

0.48

Dividendenrendite

3.5

Gewinnspanne

9.279

Angestellte

47,029

EBITDA

180B

337B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+76.4% upside

Dividenden

By Acuity

Dividendenrendite

Branchendurchschnitt

3.50%

2.23%

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-192M

56B

Vorheriger Eröffnungskurs

14.25

Vorheriger Schlusskurs

18.05

Nachrichtenstimmung

By Acuity

100%

0%

329 / 340 Ranking in Healthcare

Takeda Pharmaceutical Co Ltd ADR Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

18. Aug. 2026, 23:56 UTC

News

Exelixis shares are lower in after-market hours following BMO's Market Perform rating. Broader market pressures from rising bond yields also weigh on the stock.

18. Aug. 2026, 23:56 UTC

News

Carvana Co's shares are higher in after-market trading amid concerns over major shareholder Mark Walter's federal investigation and potential stake sale valued at $2 billion.

18. Aug. 2026, 23:52 UTC

News
Social Media

IONQ partners with CMC Microsystems to enhance cloud quantum computing access in Canada. Shares are lower in after-market hours following the announcement.

18. Aug. 2026, 23:51 UTC

News
Social Media
Event

La-Z-Boy Inc reported a net loss of $2.29 million and lowered its revenue guidance, leading shares to trade lower in after-market hours.

18. Aug. 2026, 23:51 UTC

News

JBS N.V. has proposed to acquire an 18% stake in Pilgrim's Pride, offering 2.086 shares per Pilgrim's Pride share. Shares are higher in after-market trading.

18. Aug. 2026, 23:46 UTC

News

Blue Owl Capital shares are lower in after-market hours following a recent bond issuance of $400 million by its affiliate. Analysts estimate fair value at $12.38.

18. Aug. 2026, 23:41 UTC

News
Social Media

UGI Corp shares rose in after-market trading on news of KKR's unsolicited $9 billion acquisition proposal, valuing the company at about $42.50 per share.

18. Aug. 2026, 23:41 UTC

News

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

18. Aug. 2026, 23:36 UTC

News

BMO Capital initiated coverage on Alnylam Pharmaceuticals with an Outperform rating and a price target of $318. Shares are higher in after-market trading.

18. Aug. 2026, 23:36 UTC

News
Correlated Moves

SPDR Gold Shares trade lower in after-market hours as Indonesia holds rates steady, while rising crude oil prices may affect inflation and market dynamics.

18. Aug. 2026, 23:21 UTC

News
Correlated Moves

Silver is trading lower in after-market hours, reflecting a decline alongside the United States Copper Index Fund. Silver remains above its 20-day moving average.

18. Aug. 2026, 23:21 UTC

Event
News

Jack Henry & Associates projects fiscal 2027 GAAP sales of $2.684 billion to $2.709 billion, exceeding analyst estimates, as shares rise in after-market hours.

18. Aug. 2026, 23:21 UTC

News

Evolution Petroleum shares are lower in after-market trading following a public offering announcement to fund a $16 million acquisition in the Midland Basin.

18. Aug. 2026, 23:21 UTC

News

Norfolk Southern completed its Living Shoreline project and advanced in after-market trading, showing strength above its 20-day moving average.

18. Aug. 2026, 23:21 UTC

News

Enovix Corporation shares rise in after-market hours as executives reassure investors and reaffirm Q3 2026 revenue guidance of $9.0 million to $10.0 million.

18. Aug. 2026, 23:11 UTC

Correlated Moves
News

Photronics Inc is facing a potential securities fraud lawsuit, contributing to a decline in after-market trading. The Russell 2000 Index also showed a slight decrease.

18. Aug. 2026, 23:06 UTC

News
Social Media

Eli Lilly shares are lower in after-market hours amid scrutiny over its planned acquisition of Sangamo's gene therapy technologies from Genentech and others.

18. Aug. 2026, 23:02 UTC

News
Correlated Moves
Social Media

Price target raised to $1,250; shares lower in after-market.

18. Aug. 2026, 23:01 UTC

News

Toll Brothers reported third-quarter earnings of $280.1 million, exceeding expectations. Shares are trading higher in after-market hours following the results.

18. Aug. 2026, 23:01 UTC

News

Automatic Data Processing shares are lower in after-market trading despite a rebound in U.S. private-sector hiring, amid rising U.S. Treasury yields.

18. Aug. 2026, 23:01 UTC

News
Social Media

Mercury Systems shares fell after reporting a decline in net income to $798,000 and missing adjusted EPS estimates by $0.02 in after-market trading.

18. Aug. 2026, 23:01 UTC

News

Union Pacific shares are higher in after-hours trading as the Surface Transportation Board advances merger discussions with Norfolk Southern, boosting investor sentiment.

18. Aug. 2026, 23:01 UTC

News
ETF Constituents

The Vanguard Growth ETF is higher in after-market trading, supported by gains in META and AMZN, despite broader market pressures from inflation and geopolitical tensions.

18. Aug. 2026, 23:01 UTC

News
Social Media
Event

Keysight Technologies reported third-quarter revenue of $1.846 billion, exceeding expectations. Shares rose in after-market trading following the strong earnings and raised guidance.

18. Aug. 2026, 23:01 UTC

News

Blue Owl Capital shares are higher in after-market hours as Blue Owl Technology Finance prices $400 million in bonds, exceeding its $200 million target.

18. Aug. 2026, 23:01 UTC

News
Social Media

Dell Technologies shares are lower in after-market trading amid broader market pressures and rising U.S. Treasury yields ahead of its September 1 earnings call.

18. Aug. 2026, 23:01 UTC

News

Kennametal Inc appointed Dawne S. Hickton and Richard J. Harshman to its Board of Directors, prompting shares to advance in after-market trading.

18. Aug. 2026, 22:02 UTC

News

Curtiss-Wright Corp announced a $100 million expansion of its share repurchase program, raising total buybacks to $260 million for 2026. Shares are higher in after-market trading.

18. Aug. 2026, 21:03 UTC

News

Geron Corporation's shares are lower in after-market trading following the grant of stock options to new employees at an exercise price of $1.53.

18. Aug. 2026, 21:01 UTC

News

Cinemark Holdings Inc. shares rise after *Spider-Man: Brand New Day* becomes the highest-grossing domestic film in the company's history within three weeks of release.

Peer-Vergleich

Kursveränderung

Takeda Pharmaceutical Co Ltd ADR Prognose

Kursziel

By TipRanks

76.4% Vorteil

12-Monats-Prognose

Durchschnitt 31.84 USD  76.4%

Hoch 42.684 USD

Tief 21 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Takeda Pharmaceutical Co Ltd ADR – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat